From Wikipedia, the free encyclopedia
Jump to: navigation, search
MediGene AG
Type Aktiengesellschaft
Traded as FWBMDG
Industry Biotechnology
Predecessors Munich Gene Center
Founded 1994 (1994)
Headquarters Martinsried, Germany
Key people Frank Mathias (CEO), Ernst-Ludwig Winnacker (Chairman of the supervisory board)
Products Pharmaceuticals for treatment of cancer and autoimmune diseases
Revenue €37.9 million (2009)[1]
Operating income Decrease (€19.6 million) (2009)[1]
Profit Decrease (€22.0 million) (2009)[1]
Employees 110 (end 2009)[1]

MediGene AG is a German biotechnology company established in 1994. It is involved in the development of drugs to treat pancreatic cancer.[2] The company has two marketed products: Eligard (leuprorelin) for prostate cancer and Veregen (sinecatechins) for genital warts. It has three other products in clinical development for the treatment of hormone-resistant breast cancer, pancreatic cancer, and rheumatoid arthritis.


  1. ^ a b c d "Annual Report 2009". MediGene. Retrieved 22 August 2010. 
  2. ^ "MediGene drug extends pancreatic cancer survival". Reuters. 2008-09-18. 

External links[edit]